A Multicenter Experience with Long-Acting Somatostatin Analogues in Patients with Congenital Hyperinsulinism

作者：van der Steen Ivo^*; van Albada Mirjam E.; Mohnike Klaus; Christesen Henrik Thybo; Empting Susann; Salomon-Estebanez Maria; Rasmussen Amalie Greve; Stuart Annemarie Verrijn; van der Linde Annelieke A. A.^*; Banerjee Indraneel; Boot Annemieke M.

来源：Hormone Research in Paediatrics, 2018, 89(2): 82-89.

DOI：10.1159/000485184

• Congenital hyperinsulinism
• Somatostatin analogue
• Glycemic control
• Lanreotide
• Sandostatin-LAR
• Treatment

Background/Aims: Congenital hyperinsulinism (CHI) is a rare disease characterized by recurrent severe hypoglycemia. In the diffuse form of CHI, pharmacotherapy is the preferred choice of treatment. Long-acting somatostatin analogues have been used in children as off-label medication. However, the efficacy, outcomes, and adverse effect profiles of long-acting somatostatin analogues have not been described in multicentered studies. The aim of this retrospective study is to summarize the experience with long-acting somatostatin analogues in a large group of children with CHI. Methods: Data were obtained retrospectively from 27 patients with CHI who received long-acting somatostatin analogues in 6 different centers in Europe. These included information on glycemic stability, auxology, and adverse effect profile in clinical follow-up assessments. Results: Blood glucose control improved in most patients (89%). No life-threatening side effects occurred. Thirteen patients (48%) experienced side effects; in 3 patients (11%), the side effects were the main reason for discontinuation of the treatment. The most frequent side effect was elevated liver enzymes (n = 10, 37%). Conclusion: Long-acting somatostatin analogues are effective in glycemic control of patients with CHI. However, in 37% of all patients increased liver enzymes were observed. It is important to monitor liver function in all patients receiving long-acting somatostatin analogue therapy.

• 出版日期2018